Article

Jyoti D. Patel on the Progress of Immunotherapy in NSCLC

Author(s):

Jyoti D. Patel

Jyoti D. Patel, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the progress of immunotherapy as treatment for patients with non-small cell lung cancer.

Jyoti D. Patel, ASCO expert, associate professor, Northwestern University Feinberg School of Medicine, discusses the progress of immunotherapy as treatment for patients with non-small cell lung cancer (NSCLC). Patel is reporting on data presented at the 2015 annual meeting of the American Society of Clinical Oncology, a gathering of nearly 30,000 oncology professionals in Chicago.

Related Videos
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of woman.
Image of woman.
Image of woman.
Image of man wearing baseball cap backwards.
Image of smiling doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
Image od grey haired Doctor.
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.
Related Content
Illustration of lungs.
April 1st 2025

Tagrisso May Improve Survival in Advanced EGFR-Mutant NSCLC

Alex Biese
Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in EGFR+ advanced or metastatic NSCLC: © SciePro - stock.adobe.com
March 31st 2025

First-line Rybrevant Combo Extends Survival in Advanced Lung Cancer

Ryan Scott
First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
CAN-2409 elicited responses among patients with pretreated stage 3/4 non–small cell lung cancer: © steph_photographis - stock.adobe.com
March 27th 2025

CAN-2409 Elicits Survival Responses In NSCLC

Alex Biese
Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 non–small cell lung cancer.
Image of cancer vaccine.
March 25th 2025

New Cancer Vaccine, EVM14, Cleared for Investigational Drug Application

Spencer Feldman
EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach this stage.